Health Condition 1: E282- Polycystic ovarian syndrome
Conditions
Interventions
None listed
Sponsors
Rishikul Campus UAU Haridwar
Eligibility
Inclusion criteria
Inclusion criteria: Unmarried Married Patients Patient fulfilling the diagnostic criteria [ASRM ESHRE] 2003 Oligo and or anovulation Hyperandrogenism (clinical andor biochemical) Polycystic ovaries {Ovarian volume more than 10 cm cube} a Multi follicular cyst more than 12 b Cyst Size 2-9mm in diameter
Exclusion criteria
Exclusion criteria: Female of age group less than 15 years or more than 40 years. Patient has gross structural anomalies of uterus and appendages. Those had primary amenorrhea. Pelvic disease-Fibroids, benign malignant tumours of ovary, STDs (Sexually Transmitted Diseases), PID (Pelvic Inflammatory Disease), Endometriosis etc. Patient with IUCD (Intra-Uterine Contraceptive Device) Systemic disease- Bleeding disorder, Diabetes mellitus, Hypertension, Tuberculosis, Heart disease etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of drugs for menstrual irregularity and anovulation is to bring back a healthy, predictable menstrual cycle through restoration of ovulation, which also protects reproductive and?overall?health.Timepoint: 1 MONTH | — |
Secondary
| Measure | Time frame |
|---|---|
| menstrual irregularity & anovulation is to bring back a healthy, predictable menstrual cycle through restoration of ovulation, which also protects reproductive and?overall?health. Timepoint: 2 MONTH | — |
Countries
India
Contacts
Public ContactAnjali Parmar
Rishikul Campus Haridwar
Outcome results
None listed